Emactuzumab is under clinical development by SynOx Therapeutics and currently in Phase II for Transitional Cell Carcinoma (Urothelial Cell Carcinoma). According to GlobalData, Phase II drugs for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) have an 18% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Emactuzumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Emactuzumab overview
Emactuzumab (RG-7155, RO5509554) is under development for the treatment of solid tumors like metastatic ovarian cancer, bladder cancer, gastric cancer, soft tissue sarcoma, colorectal cancer, pancreatic cancer, melanoma or malignant mesothelioma, tenosynovial giant cell tumor, pigmented villonodular synovitis and relapsed or refractory platinum-resistant ovarian cancer, fallopian tube cancer or primary peritoneal cancer clear cell adenocarcinoma, endometrioid adenocarcinoma, malignant Brenner's tumor, mixed epithelial carcinoma, mucinous adenocarcinoma, serous adenocarcinoma, transitional cell carcinoma, undifferentiated carcinoma. The drug candidate is administered through intravenous route. It is a new molecular entity (NME). RG7155 acts on targeting colony stimulating factor-1 receptor (CSF-1R). It was also under development for treatment of relapsed or refractory follicular lymphoma, metastatic triple negative breast cancer, metastatic pancreatic ductal adenocarcinoma.
SynOx Therapeutics overview
SynOx Therapeutics (SynOx) is a biopharmaceutical company. It develops emactuzumab, for the treatment of diffuse tenosynovial giant cell tumours (TGCT), also known as pigmented villonodular synovitis (PVNS) and other indications. SynOx is headquartered in Dublin, Ireland.
For a complete picture of Emactuzumab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
